Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$2.00
-5.9%
$2.27
$0.40
$3.10
$329.00M2.133.30 million shs2.16 million shs
CureVac N.V. stock logo
CVAC
CureVac
$5.43
-0.3%
$5.44
$2.37
$5.72
$1.21B2.53944,209 shs466,793 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$31.93
-1.6%
$28.31
$16.16
$32.95
$1.29B0.8258,880 shs128,799 shs
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$7.83
+1.0%
$5.53
$2.48
$7.96
$1.26B0.652.55 million shs1.41 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
0.00%+10.99%-11.67%-4.93%+75.21%
CureVac N.V. stock logo
CVAC
CureVac
0.00%-0.73%-0.37%+33.01%+64.35%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
0.00%+5.84%+11.24%+39.67%+55.01%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
0.00%+0.91%+54.38%+60.46%+169.10%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3.8621 of 5 stars
3.51.00.04.70.61.71.3
CureVac N.V. stock logo
CVAC
CureVac
4.6409 of 5 stars
4.15.00.04.91.60.01.3
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
3.4317 of 5 stars
0.92.02.51.12.03.32.5
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
3.4214 of 5 stars
1.43.00.04.23.42.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3.00
Buy$5.75188.22% Upside
CureVac N.V. stock logo
CVAC
CureVac
2.20
Hold$6.8325.96% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.83
Reduce$24.40-23.57% Downside
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
2.83
Moderate Buy$7.08-9.48% Downside

Current Analyst Ratings Breakdown

Latest CTMX, PAHC, XERS, and CVAC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/19/2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$7.00 ➝ $9.00
8/12/2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
7/31/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$7.00
7/7/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$25.00 ➝ $35.00
6/26/2025
CureVac N.V. stock logo
CVAC
CureVac
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Neutral$12.00 ➝ $5.50
6/25/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$21.00 ➝ $26.00
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas Exane
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Neutral$24.00
6/13/2025
CureVac N.V. stock logo
CVAC
CureVac
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$7.00 ➝ $5.00
6/12/2025
CureVac N.V. stock logo
CVAC
CureVac
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform
6/12/2025
CureVac N.V. stock logo
CVAC
CureVac
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$141.10M2.33$0.34 per share5.86($0.01) per share-199.50
CureVac N.V. stock logo
CVAC
CureVac
$579.18M2.10$0.87 per share6.23$3.36 per share1.61
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.19B1.09$2.08 per share15.36$6.34 per share5.04
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$246.03M5.14N/AN/A($0.20) per share-39.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$31.87M$0.563.56N/AN/A34.04%158.70%36.04%11/6/2025 (Estimated)
CureVac N.V. stock logo
CVAC
CureVac
$175.50M$0.965.64N/AN/A38.21%29.57%25.41%11/11/2025 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$2.42M$0.7840.9315.200.542.68%30.51%6.89%8/27/2025 (Estimated)
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$54.84M-$0.21N/AN/AN/A-13.01%N/A-8.00%N/A

Latest CTMX, PAHC, XERS, and CVAC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/27/2025Q4 2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.52N/AN/AN/A$362.24 millionN/A
8/21/2025Q2 2025
CureVac N.V. stock logo
CVAC
CureVac
-$0.15-$0.30-$0.15-$0.30$4.27 million$1.41 million
8/7/2025Q2 2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$0.03-$0.01+$0.02-$0.01$64.58 million$67.71 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/AN/AN/AN/AN/A
CureVac N.V. stock logo
CVAC
CureVac
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.50%N/A61.54%N/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/AN/AN/AN/AN/A

Latest CTMX, PAHC, XERS, and CVAC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/29/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.121.71%9/3/20259/3/20259/24/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/A
4.20
4.20
CureVac N.V. stock logo
CVAC
CureVac
0.05
6.17
6.16
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.67
2.91
1.23
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/A
1.95
1.24

Institutional Ownership

CompanyInstitutional Ownership
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
67.77%
CureVac N.V. stock logo
CVAC
CureVac
17.26%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
42.75%

Insider Ownership

CompanyInsider Ownership
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
6.60%
CureVac N.V. stock logo
CVAC
CureVac
N/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.07%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
6.47%
CompanyEmployeesShares OutstandingFree FloatOptionable
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
170164.91 million154.03 millionOptionable
CureVac N.V. stock logo
CVAC
CureVac
880224.34 millionN/AOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1,94040.53 million20.24 millionOptionable
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
290161.48 million154.12 millionOptionable

Recent News About These Companies

Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
FY2025 EPS Estimates for Xeris Biopharma Boosted by Analyst
Q3 EPS Estimates for Xeris Biopharma Decreased by Analyst
FY2025 EPS Estimate for Xeris Biopharma Increased by Analyst
Q3 EPS Estimates for Xeris Biopharma Lowered by Analyst
HC Wainwright Estimates Xeris Biopharma Q3 Earnings
HC Wainwright Comments on Xeris Biopharma Q3 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

CytomX Therapeutics stock logo

CytomX Therapeutics NASDAQ:CTMX

$2.00 -0.13 (-5.90%)
As of 03:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

CureVac stock logo

CureVac NASDAQ:CVAC

$5.42 -0.02 (-0.28%)
As of 03:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$31.92 -0.54 (-1.65%)
As of 03:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Xeris Biopharma stock logo

Xeris Biopharma NASDAQ:XERS

$7.82 +0.08 (+0.97%)
As of 03:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.